Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia
Lı́dia Ruiz, Lı́dia Ruiz, Eunate Gallardo‐Vara, Eunate Gallardo‐Vara, Elisa Rossi, Elisa Rossi, David M. Smadja, David M. Smadja, Luisa M. Botella, Luisa M. Botella, Carmelo Bernabéu, Carmelo Bernabéu (2017). Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. , 21(10), DOI: https://doi.org/10.1080/14728222.2017.1365839.
Article154 days agoEndoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia
Lı́dia Ruiz, Lı́dia Ruiz, Eunate Gallardo‐Vara, Eunate Gallardo‐Vara, Elisa Rossi, Elisa Rossi, David M. Smadja, David M. Smadja, Luisa M. Botella, Luisa M. Botella, Carmelo Bernabéu, Carmelo Bernabéu (2017). Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. , 21(10), DOI: https://doi.org/10.1080/14728222.2017.1365839.
Article154 days agoEfficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC
Lı́dia Ruiz, Joan Romeu, Javier Martínez‐Picado, Jean‐Claude Schmit, Anne‐Mieke Vandamme, Montserrat Balagué, Cecilia Cabrera, Teresa Puig, Cristina Tural, Antònia Segura, Guillem Sirera, De Clercq Erik, Bonaventura Clotet (1996). Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. , 10(14), DOI: https://doi.org/10.1097/00002030-199612000-00003.
Article28 days agoPatient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir
Kristel Van Laethem, Myriam Witvrouw, Jan Balzarini, Jean‐Claude Schmit, S Sprecher, Philippe Hermans, Manuel Leal, Thomas Harrer, Lı́dia Ruiz, Bonaventura Clotet, Marc Van Ranst, Jan Desmyter, De Clercq Erik, Anne‐Mieke Vandamme (2000). Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. , 14(4), DOI: https://doi.org/10.1097/00002030-200003100-00027.
Letter28 days agoBaseline HIV Type 1 Genotypic Resistance to a Newly Added Nucleoside Analog Is Predictive of Virologic Failure of the New Therapy
Kristien Van Vaerenbergh, Kristel Van Laethem, Eric Van Wijngaerden, Jean‐Claude Schmit, F Schneider, Lı́dia Ruiz, Bonaventura Clotet, Chris Verhofstede, Filip Van Wanzeele, G. M Uyldermans, P. Simons, Lieven Stuyver, P. Hermans, Christopher Evans, De Clercq Erik, Jan Desmyter, Anne‐Mieke Vandamme (2000). Baseline HIV Type 1 Genotypic Resistance to a Newly Added Nucleoside Analog Is Predictive of Virologic Failure of the New Therapy. , 16(6), DOI: https://doi.org/10.1089/088922200308945.
Article28 days ago